Omalizumab administration in Churg-Strauss syndrome.
Pedro
P
Giavina-Bianchi
Jorge
J
Kalil
D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000188:drug therapy; D015267:Churg-Strauss Syndrome / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000069444:Omalizumab
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab